Form 4: Biolife Solutions EVP Sells Shares Under 10b5-1 Plan

Biolife Solutions' Executive Vice President and Chief Scientific Officer, Aby J. Mathew, sold 404 shares of common stock at $27.02 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Aby J. Mathew, Executive Vice President and Chief Scientific Officer of Biolife Solutions, sold 404 shares of common stock.
• The sale occurred on January 6, 2025, at a price of $27.02 per share.
• The transaction was executed under a Rule 10b5-1 trading plan adopted by Mr. Mathew on January 3, 2023.
• This sale was to cover tax withholding obligations related to the vesting of restricted stock.
• Following the transaction, Mr. Mathew directly owns 262,715 shares of Biolife Solutions common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-existing plan, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who use 10b5-1 plans to manage their stock holdings and tax obligations. It does not indicate any change in the company's outlook or performance.

Comparison to Industry Standards

• Sales by executives under 10b5-1 plans are common across publicly traded companies.
• The number of shares sold is relatively small compared to the total shares held by the executive.
• The price of $27.02 is within the normal trading range for the stock.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on shareholders, employees, customers, suppliers, or creditors.

Key Dates

Keywords

Biolife Solutions, BLFS, insider trading, stock sale, Rule 10b5-1, executive, share transaction, equity securities